In AF after TAVR, edoxaban was noninferior to VKAs for a composite of adverse events but increased major bleeding
Authors: Furio Colivicchi
Journal: Annals of Internal Medicine (2022)

ACP Journal ClubFebruary 2022In AF after TAVR, edoxaban was noninferior to VKAs for a composite of adverse events but increased major bleedingFurio Colivicchi, MDFurio Colivicchi, MDSan Filippo Neri Hospital, Rome, Italy (F.C.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/J21-0014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationVan Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021;385:2150-60. https://pubmed.ncbi.nlm.nih.gov/34449183Clinical Impact RatingsCardiology: References1. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e72-e227. [PMID: 33332150] Google Scholar2. Capodanno D, Collet JP, Dangas G, et al. Antithrombotic therapy after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2021;14:1688-1703. [PMID: 34353601] Google Scholar3. Ten Berg J, Sibbing D, Rocca B, et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. Eur Heart J. 2021;42:2265-9. [PMID: 33822924] Google Scholar4. Collet JP. ATLANTIS: Anti-thrombotic strategy to lower all cardiovascular and neurologic ischemic and hemorrhagic events after trans-aortic valve implantation for aortic stenosis: a randomized, open-label, phase 3 trial. American College of Cardiology Virtual Annual Scientific Session (ACC 2021), 15 May 2021. Google Scholar5. Dangas GD, Tijssen JGP, Wöhrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120-9. [PMID: 31733180] Google Scholar6. Aisenberg J, Chatterjee-Murphy P, Friedman Flack K, et al. Gastrointestinal bleeding with edoxaban versus warfarin: results from the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). Circ Cardiovasc Qual Outcomes. 2018;11:e003998. [PMID: 29748353] Google Scholar Author, Article, and Disclosure InformationAffiliations: San Filippo Neri Hospital, Rome, Italy (F.C.)Disclosures: The commentator has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J21-0014.This article was published at Annals.org on 01 February 2022. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics February 2022Volume 175, Issue 2Page: JC22KeywordsAortic valve replacementAtrial fibrillationHemorrhageObservational studiesSafetyStenosisStrokeThrombosisVitamin K ePublished: 1 February 2022 Issue Published: February 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...